Dr. Preeshagul on Education for Biosimilars in Oncology

Video

In Partnership With:

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.

Isabel Preeshagul, DO, MBS, a thoracic medical oncologist and assistant attending at Memorial Sloan Kettering Cancer Center, discusses the need for more information about using biosimilars when treating patients with cancer.

Preeshagul finds that using biosimilars can be challenging due to a lack of information regarding what biosimilar drugs have been approved and when they should be implemented in a patient’s treatment course.

In order to get more physicians to use or consider using these types of agents, Preeshagul suggests improving the educations surrounding biosimilars. There should be guidance to aid oncologists through the implementation of the biosimilar in practice, Preeshagul concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD